Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
about
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenHuman rhinoviruses in severe respiratory disease in very low birth weight infants.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in childrenQuality assessment of published health economic analyses from South America.Cost, causes and rates of rehospitalization of preterm infants.Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infantsA review of cost-effectiveness of palivizumab for respiratory syncytial virus.Use of number needed to treat in cost-effectiveness analyses.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.Pediatricians' attitudes and costs of bronchiolitis in the emergency department: a prospective multicentre study.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.The Argentina Premature Asthma and Respiratory Team (APART): objectives, design, and recruitment results of a prospective cohort study of viruses and wheezing in very low birth weight infants.Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
P2860
Q24197915-E0FF1F8B-14BF-4D56-BE4B-10D708A750ACQ34634685-57FA8684-DAAC-4DED-ACB8-26BAB1658448Q34884984-11B91254-9584-4F91-B9DC-134745B9E7F1Q35595950-C1F9C11B-9B10-4C10-B97A-799A7070DE01Q36466893-357F3D58-F0DC-4A57-BD8C-1339DB35849AQ36918637-ED7B1D5C-810A-4EBB-BF6C-9E1CF99495A3Q37075237-0001D953-0D85-48C5-9BBF-37507185D95BQ38058838-36E95BFB-C63A-426D-9FEC-E456852B685EQ38086820-819FC6BA-723D-419D-9C16-A1BD570D679AQ38604949-E51A0A6E-471C-44CE-9173-C69EE2D7A566Q42023014-51BEB3E1-3302-412D-A932-EE640C623A74Q42259244-4C288F56-943C-43B2-93F7-6BB007BF2931Q45375474-C25D76E2-BB69-4444-9BB4-DF5120F412DCQ46186671-0400F921-E037-45B0-8A26-4113B1392268Q57570436-872B198B-B42E-4AA9-9015-1A8E93D2137E
P2860
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@en
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@nl
type
label
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@en
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@nl
prefLabel
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@en
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@nl
P2093
P1476
Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
@en
P2093
Clara Gilli
Diana Fariña
Enrique Laffaire
Gabriela Bauer
Helena González
Liliana Bouzas
Luis Novali
Susana P Rodríguez
P304
P356
10.1097/00006454-200204000-00006
P577
2002-04-01T00:00:00Z